Pharma
ELI LILLY OWNS PHARMA NOW
Eli Lilly: the current brand demand leader in pharma. Mounjaro, Zepbound, Donanemab, the $20 billion+ U.S. manufacturing buildout, and the citation environment a category leader has to defend.
EPR Editorial Team
EPRPharmaeverything-pr.com/pharma
AI communications & PR intelligence for pharma and biotech.
EPR Pharma is the dedicated pharma and biotech title of the Everything-PR network — daily reporting, research, and AI-visibility analysis on how pharma and biotech companies earn presence inside ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews.
By EPR Editorial Team
EPR Pharma
The Guide
EPR Pharma: a complete overview
By EPR Editorial Team·Industry briefing
Frequently Asked Questions
What is EPR Pharma?▾
The pharma and biotech publication of the Everything-PR network, covering AI communications and PR for pharma and biotech since 2009.
What does EPR Pharma cover?▾
Pharma, biotech, and life sciences — plus regulatory, patient, and crisis and AI visibility.
What is AI communications in pharma and biotech?▾
Earning brand presence inside AI answer engines — GEO, AI-visibility research, and citable earned media — for pharma and biotech brands.
Full Archive
All articles in EPR Pharma
15 articles
Pharma
Novo Nordisk vs Eli Lilly: Who Owns the GLP-1 Answer
Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.
Pharma
WebMD Is Losing to Reddit on Drug Questions
AI engines increasingly surface Reddit alongside — and sometimes ahead of — WebMD on medication prompts. This is a Citation Share shift, not a clinical-authority shift. Visibility is not clinical authority. What the new patient surface means for pharma communications.
Pharma
Pfizer Still Owns Pharma AI
The Pharma AI Citation Share Study — 25 brands across five engines. Pfizer leads. Why incumbent pharma authority compounds inside AI answers.
Pharma
Why Pfizer's 2017 Vaccine Charity Move Still Wins in AI Answers
Pfizer's 2017 Prevnar 13 humanitarian price cut is still in AI answers nine years later. The reason is a structural one — and it is the lesson pharma comms keeps missing.
Pharma
What Pfizer's 2016 NYC Headquarters Move Says About Healthcare AI
Pfizer's 2016 NYC headquarters move was misframed as a corporate retreat. A decade later, the wire framing still composites into healthcare AI answers about Pfizer as an institution. That is how the source layer works.
Pharma
The Mylan EpiPen Pricing Crisis: A Pharmaceutical Communications Case Study
The Mylan EpiPen pricing crisis of 2016 — from $100 in 2009 to $600+ in 2016, the congressional hearings, the defensive CNBC interview, the generic EpiPen response, the eventual Viatris merger. Four enduring lessons for pharmaceutical crisis communications.
Pharma
Pfizer's Scientist-Forward Pivot Was an AI-Era Move Before AI
Pfizer's 2016 scientist-forward pivot was treated as reputation rescue at the time. In the AI retrieval era it turned out to be the operating model. Same instinct, much higher stakes.
Pharma
Pharma: EPR's Coverage of Pfizer, Eli Lilly, J&J, Purdue, Moderna, GLP-1, and the Industry
If you are one of the households still watching television programing, you know pharmaceuticals feature big on their amount of ad time.
Pharma
Wu-Tang Clan Sells Album to Notorious Pharmaceutical CEO Martin Shkreli
The Wu-Tang Clan album Once Upon A Time In Shaolin holds a long and storied legend.